サマリー

2030年までの眼科外用治療薬市場予測
市場概要
眼科用局所治療薬は、予測期間（2023年〜2030年）に7.25%の大幅なCAGRを記録すると推定される。
この市場は、高齢者人口の増加や眼科疾患の拡大など、いくつかの要素によって牽引されています。
屈折障害、ドライアイ、緑内障、眼過敏症、加齢黄斑変性症などの眼科的問題の一般性が国際的に高まっており、これが市場発展の原動力となっている。2021年10月のWHOの発表によると、約22億人が視力低下の弊害を経験している。視力障害の主な原因は屈折障害と緑内障であり、この2つは眼科用局所修復アイテムが入手可能である。基本的に、緑内障は普遍的に不可逆的な視覚障害の主な原因である。公共緑内障調査によって示されるように、300万人以上のアメリカ人が緑内障を患っている。2021年のWHOによると、世界中で770万人以上の人が緑内障の弊害を経験しています。緑内障の最も広く認識されている治療法は、β遮断薬、プロスタグランジン、Rho-キナーゼ阻害薬などの緑内障の悪化を抑えることができる治療薬の点眼薬です。

市場細分化
眼科外用治療薬の市場細分化は、タイプに基づいて、偽涙、過敏症対策、抗毒素点眼、緩和、抗緑内障、その他が組み込まれています。疾患タイプ別では、ドライアイ、眼精疲労、緑内障、眼疾患、網膜疾患、ぶどう膜炎などがあります。投与形態の観点から、世界の眼科局所治療薬産業は点眼薬、ゲル、軟膏、その他に分けられます。
眼科外用治療薬の市場区分は、流通チャネルの観点から、クリニック薬局、薬局、オンライン薬局、その他に分けられます。
地域別インサイト

北米の眼科外用治療薬市場は、2022年に最も大きなパイを占めました。主な変動要因は、眼病患者の増加、老人人口の増加、同地域における膨大な数の市場プレイヤーの存在である。さらに、眼科疾患の増加により、北米の眼科用局所治療薬に対する市場の関心が高まっている。老年人口の増加、検眼における革新的な研究の進展、救急クリニックのドラッグストアにおける眼科治療薬の利用拡大などの要因が、米国における眼科局所治療薬への関心を拡大させるものと思われます。
欧州の眼科用局所治療薬市場は、2番目に大きなパイを占めています。その理由は、先進国における老人人口の拡大、医療サービスのグローバル化、糖尿病やその他の合併症の増加です。
アジア太平洋地域の眼科局所治療薬市場は、2023年から2030年にかけて最も急速に発展するものと思われます。これは、眼科疾患の重量の拡大や買い手の意識の高まり、最先端の技術革新の受け入れが進んでいるためです。各組織は、患者のための新しい治療法の選択肢を生み出し、普及させるために、重要な取り組みを行っています。

主要プレイヤー
眼科用局所治療薬市場の主要企業には、参天製薬株式会社（日本）、Sun Pharmaceutical Industries Ltd. （米国）、Sun Pharmaceutical Industries, Inc.(日本）、Sun Pharmaceutical Industries Ltd（インド）、Novartis AG（スイス）、AbbVie（米国）、Bausch & Lomb Incorporated（米国）、Amneal Pharmaceuticals,LLC（米国）、Teva Pharmaceutical Industries Ltd.（スイス）、Alcon（スイス）、AbbVie Inc.(イスラエル）、Alcon（スイス）、Akorn Operating Company LLC（米国）、Viatris Inc.

ページTOPに戻る

目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 RISE IN GERIATRIC POPULATION

4.2.2 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS

4.3 RESTRAINTS

4.3.1 LACK OF AWARENESS REGARDING EYE DISORDERS

4.4 OPPORTUNITIES

4.4.1 GROWING NUMBER OF TOPICAL DRUGS IN THE PIPELINE

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE OPHTHALMIC TOPICAL THERAPEUTICS MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON PRODUCTTION

5.3.3 IMPACT ON MARKET PLAYERS

6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE

6.1 OVERVIEW

6.2 ARTIFICIAL TEARS

6.3 ANTI-ALLERGY

6.4 ANTIBIOTIC DROPS

6.5 ANTI-INFLAMMATORY

6.6 ANTIGLAUCOMA

6.7 OTHERS

7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE

7.1 OVERVIEW

7.2 DRY EYE

7.3 EYE ALLERGY

7.4 GLAUCOMA

7.5 EYE INFECTION

7.6 RETINAL DISORDERS

7.7 UVEITIS

7.8 OTHERS

8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM

8.1 OVERVIEW

8.2 EYE DROPS

8.3 GELS

8.4 OINTMENTS

8.5 OTHERS

9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 HOSPITAL PHARMACIES

9.3 DRUG STORES

9.4 ONLINE PHARMACIES

9.5 OTHERS

10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION

10.1 OVERVIEW

10.2 NORTH AMERICA

10.2.1 US

10.2.2 CANADA

10.3 EUROPE

10.3.1 GERMANY

10.3.2 UK

10.3.3 FRANCE

10.3.4 ITALY

10.3.5 SPAIN

10.3.6 REST OF EUROPE

10.4 ASIA-PACIFIC

10.4.1 JAPAN

10.4.2 CHINA

10.4.3 INDIA

10.4.4 AUSTRALIA

10.4.5 SOUTH KOREA

10.4.6 REST OF ASIA-PACIFIC

10.5 REST OF THE WORLD

10.5.1 MIDDLE EAST

10.5.2 AFRICA

10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

11.2 COMPETITIVE BENCHMARKING

11.3 MAJOR GROWTH STRATEGY IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET

11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET

11.5 KEY DEVELOPMENT ANALYSIS

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

11.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS

11.6.2 PARTNERSHIP/COLLABORATION

11.6.3 BUSINESS EXPANSIONS/AGREEMENTS

11.6.4 MERGERS & ACQUISITIONS

11.7 MAJOR PLAYERS SALES ANALYSIS

11.7.1 SALES & OPERATING INCOME

11.8 MAJOR PLAYERS R&D ANALYSIS

12 COMPANY PROFILES

12.1 SANTEN PHARMACEUTICAL CO., LTD.

12.1.1 COMPANY OVERVIEW

12.1.2 FINANCIAL OVERVIEW

12.1.3 PRODUCTS/SERVICES OFFERED

12.1.4 KEY DEVELOPMENTS

12.1.5 KEY STRATEGIES

12.2 SUN PHARMACEUTICAL INDUSTRIES LTD

12.2.1 COMPANY OVERVIEW

12.2.2 FINANCIAL OVERVIEW

12.2.3 PRODUCTS/SERVICES OFFERED

12.2.4 KEY DEVELOPMENTS

12.2.5 KEY STRATEGIES

12.3 NOVARTIS AG

12.3.1 COMPANY OVERVIEWS

12.3.2 FINANCIAL OVERVIEW

12.3.3 PRODUCTS/SERVICES OFFERED

12.3.4 KEY DEVELOPMENTS

12.3.5 SWOT ANALYSIS

12.3.6 KEY STRATEGIES

12.4 ABBVIE INC.

12.4.1 COMPANY OVERVIEW

12.4.2 FINANCIAL OVERVIEW

12.4.3 PRODUCTS OFFERED

12.4.4 KEY DEVELOPMENTS

12.4.5 SWOT ANALYSIS

12.4.6 KEY STRATEGIES

12.5 BAUSCH & LOMB INCORPORATED

12.5.1 COMPANY OVERVIEW

12.5.2 FINANCIAL OVERVIEW

12.5.3 PRODUCTS OFFERED

12.5.4 KEY DEVELOPMENTS

12.5.5 SWOT ANALYSIS

12.5.6 KEY STRATEGIES

12.6 AMNEAL PHARMACEUTICALS LLC.

12.6.1 COMPANY OVERVIEW

12.6.2 FINANCIAL OVERVIEW

12.6.3 PRODUCTS/SERVICES OFFERED

12.6.4 KEY DEVELOPMENTS

12.6.5 KEY STRATEGIES

12.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.

12.7.1 COMPANY OVERVIEW

12.7.2 FINANCIAL ANALYSIS

12.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.7.4 KEY DEVELOPMENTS

12.7.5 SWOT ANALYSIS

12.7.6 KEY STRATEGIES

12.8 ALCON

12.8.1 COMPANY OVERVIEW

12.8.2 FINANCIAL OVERVIEW

12.8.3 PRODUCTS/SERVICES/SOLUTIONS 0FFERED

12.8.4 KEY DEVELOPMENTS

12.8.5 SWOT ANALYSIS

12.8.6 KEY STRATEGIES

12.9 AKORN OPERATING COMPANY LLC

12.9.1 COMPANY OVERVIEW

12.9.2 FINANCIAL OVERVIEW

12.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.9.4 KEY DEVELOPMENTS

12.9.5 KEY STRATEGIES

12.10 VIATRIS INC.

12.10.1 COMPANY OVERVIEW

12.10.2 FINANCIAL OVERVIEW

12.10.3 PRODUCTS/SERVICES OFFERED

12.10.4 KEY DEVELOPMENTS

12.10.5 KEY STRATEGIES

13 APPENDIX

13.1 REFERENCES

13.2 RELATED REPORTS

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2030 (USD BILLION)
TABLE 4 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ARTIFICIAL TEARS, BY REGION, 2019–2030 (USD BILLION)
TABLE 5 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTI-ALLERGY, BY REGION, 2019–2030 (USD BILLION)
TABLE 6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTIBIOTIC DROPS, BY REGION, 2019–2030 (USD BILLION)
TABLE 7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTI-INFLAMMATORY, BY REGION, 2019–2030 (USD BILLION)
TABLE 8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTIGLAUCOMA, BY REGION, 2019–2030 (USD BILLION)
TABLE 9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019–2030 (USD BILLION)
TABLE 10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019–2030 (USD BILLION)
TABLE 11 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR DRY EYE, BY REGION, 2019–2030 (USD BILLION)
TABLE 12 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE ALLERGY, BY REGION, 2019–2030 (USD BILLION)
TABLE 13 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR GLAUCOMA, BY REGION, 2019–2030 (USD BILLION)
TABLE 14 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE INFECTION, BY REGION, 2019–2030 (USD BILLION)
TABLE 15 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR RETINAL DISORDERS, BY REGION, 2019–2030 (USD BILLION)
TABLE 16 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR UVEITIS, BY REGION, 2019–2030 (USD BILLION)
TABLE 17 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019–2030 (USD BILLION)
TABLE 18 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019–2030 (USD BILLION)
TABLE 19 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE DROPS, BY REGION, 2019–2030 (USD BILLION)
TABLE 20 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR GELS, BY REGION, 2019–2030 (USD BILLION)
TABLE 21 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OINTMENTS, BY REGION, 22019–2030 (USD BILLION)
TABLE 22 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019–2030 (USD BILLION)
TABLE 23 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019–2030 (USD BILLION)
TABLE 24 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019–2030 (USD BILLION)
TABLE 25 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR DRUG STORES, BY REGION, 2019–2030 (USD BILLION)
TABLE 26 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019–2030 (USD BILLION)
TABLE 27 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019–2030 (USD BILLION)
TABLE 28 GLOBAL: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION, 2019–2030 (USD BILLION)
TABLE 29 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
TABLE 30 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 31 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 32 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 33 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 34 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 35 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 36 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 37 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 38 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 39 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 40 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 41 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 42 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2030 (USD BILLION)
TABLE 43 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 44 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 45 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 46 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 47 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 48 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 49 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 50 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 51 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 52 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 53 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 54 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 55 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 56 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 57 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 58 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 59 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 60 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 61 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 62 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 63 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 64 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 65 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 66 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 67 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 68 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 69 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 70 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 71 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2030 (USD BILLION)
TABLE 72 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2030 (USD BILLION)
TABLE 73 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019–2030 (USD BILLION)
TABLE 74 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019–2030 (USD BILLION)
TABLE 75 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019–2030 (USD BILLION)
TABLE 76 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 77 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 78 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 79 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 80 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 81 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 82 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 83 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 84 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 85 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 86 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 87 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 88 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 89 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 90 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 91 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
TABLE 92 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030 (USD BILLION)
TABLE 93 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 94 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 95 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
TABLE 96 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 97 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 98 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 99 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
TABLE 100 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY 2019-2030(USD BILLION)
TABLE 101 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030(USD BILLION)
TABLE 102 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030(USD BILLION)
TABLE 103 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
TABLE 104 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
TABLE 105 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
TABLE 106 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030 (USD BILLION)
TABLE 107 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
TABLE 108 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
TABLE 109 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
TABLE 110 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030(USD BILLION)
TABLE 111 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
TABLE 112 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030 (USD BILLION)
TABLE 113 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
TABLE 114 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030 (USD BILLION)
TABLE 115 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030 (USD BILLION)
TABLE 116 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
TABLE 117 MAJOR MANUFACTURERS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
TABLE 118 MOST ACTIVE PLAYER IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
TABLE 119 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS
TABLE 120 PARTNERSHIP/COLLABORATION
TABLE 121 BUSINESS EXPANSIONS/ AGREEMENTS
TABLE 122 MERGERS & ACQUISITIONS
TABLE 123 SANTEN PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED
TABLE 124 SANTEN PHARMACEUTICAL CO., LTD.: KEY DEVELOPMENTS
TABLE 125 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED
TABLE 126 GENENTECH, INC.: KEY DEVELOPMENTS
TABLE 127 NOVARTIS AG: PRODUCTS OFFERED
TABLE 128 NOVARTIS AG.: KEY DEVELOPMENTS
TABLE 129 ABBVIE INC.: PRODUCTS OFFERED
TABLE 130 ABBVIE INC.: KEY DEVELOPMENTS
TABLE 131 BAUSCH & LOMB INCORPORATED: PRODUCTS OFFERED
TABLE 132 BAUSCH & LOMB INCORPORATED: KEY DEVELOPMENTS
TABLE 133 AMNEAL PHARMACEUTICALS LLC.: PRODUCTS OFFERED
TABLE 134 AMNEAL PHARMACEUTICALS., LLC.: KEY DEVELOPMENTS
TABLE 135 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 136 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 137 ALCON: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 138 ALCON: KEY DEVELOPMENTS
TABLE 139 AKORN OPERATING COMPANY LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 140 VIATRIS INC.: PRODUCTS/SERVICES OFFERED
TABLE 141 VIATRIS INC.: KEY DEVELOPMENTS